BioNTech (NASDAQ:BNTX) Price Target Lowered to $122.00 at TD Cowen

BioNTech (NASDAQ:BNTX) had its price target decreased by investment analysts at TD Cowen from $132.00 to $122.00 in a note issued to investors on Tuesday, Benzinga reports. The firm currently has a “hold” rating on the stock. TD Cowen’s price objective would indicate a potential upside of 14.40% from the company’s previous close.

A number of other equities analysts have also weighed in on BNTX. Morgan Stanley upgraded shares of BioNTech from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $93.00 to $145.00 in a research report on Tuesday, September 24th. HSBC boosted their price target on shares of BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a research note on Monday, October 7th. HC Wainwright raised their price objective on shares of BioNTech from $113.00 to $150.00 and gave the company a “buy” rating in a research report on Monday, October 7th. JPMorgan Chase & Co. dropped their target price on BioNTech from $125.00 to $124.00 and set a “neutral” rating on the stock in a research report on Monday. Finally, Bank of America raised their price target on BioNTech from $125.00 to $150.00 and gave the company a “buy” rating in a report on Monday, September 16th. Five investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $134.69.

BioNTech Stock Down 3.9 %

BNTX stock opened at $106.64 on Tuesday. BioNTech has a 12 month low of $76.53 and a 12 month high of $131.49. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.54 and a quick ratio of 7.40. The company has a market cap of $25.36 billion, a price-to-earnings ratio of -50.78 and a beta of 0.26. The company has a fifty day moving average price of $110.63 and a 200 day moving average price of $96.23.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.81 EPS for the quarter, beating the consensus estimate of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The firm had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $514.08 million. During the same period in the prior year, the business earned $0.73 EPS. The firm’s revenue was up 38.9% compared to the same quarter last year. Sell-side analysts expect that BioNTech will post -2.93 earnings per share for the current year.

Institutional Investors Weigh In On BioNTech

Several institutional investors and hedge funds have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. increased its holdings in BioNTech by 85.9% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 68,428 shares of the company’s stock valued at $6,312,000 after acquiring an additional 31,615 shares in the last quarter. Janney Montgomery Scott LLC purchased a new position in shares of BioNTech during the 1st quarter worth approximately $314,000. Capstone Investment Advisors LLC acquired a new position in shares of BioNTech during the 1st quarter worth approximately $263,000. Gallacher Capital Management LLC lifted its stake in BioNTech by 24.5% in the 1st quarter. Gallacher Capital Management LLC now owns 3,262 shares of the company’s stock valued at $301,000 after buying an additional 642 shares in the last quarter. Finally, SG Americas Securities LLC grew its holdings in BioNTech by 610.5% during the 1st quarter. SG Americas Securities LLC now owns 70,143 shares of the company’s stock valued at $6,471,000 after buying an additional 60,270 shares during the last quarter. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.